Abstract
Prostacyclin and its stable analogues have been shown to interfere specifically with certain steps of the metastatic cascade. The antimetastatic activity of the stable prostacyclin analogue Cicaprost (Schering AG) on haematogenous metastasis in a series of tumours in rats and mice has been well established. In order to test the effect of Cicaprost on lymphogenous metastasis we chose the metastatic cell clone MTLn3 derived from the 13762NF rat mammary carcinoma. The effect of Cicaprost on prevention of lung metastasis, lymph node metastasis and primary tumour growth was investigated. Cicaprost given in daily doses of 0.01, 0.03 and 0.1 mg/kg orally, reduced the number of lung metastases in a dose-dependent manner. Whereas the median number of lung metastases in the controls was greater than 1000, Cicaprost at a dose of 0.1 mg/kg reduced the number of lung metastases to between 11 and 100. The weight of the ipsilateral axillary lymph nodes was diminished by Cicaprost to 30–50% of controls. Moreover, metastasis to the contralateral axillary lymph node was completely inhibited by Cicaprost at all three doses tested. Cicaprost did not influence the growth rate of the MTLn3 cell clone implanted into the mammary fat pad or the weight of the primary tumour at the end of treatment. In conclusion, in addition to its dose-dependent effect on haematogenous metastasis, Cicaprost strongly inhibits lymph node metastasis.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Moncada S, 1982, Biological importance of prostacyclin.British Journal of Pharmacology,76, 3–31.
Moncada S and Vane J, 1979, Pharmacology and endogenous role of prostaglandin endoperoxides, thromboxane A2 and prostacyclin.Pharmacological Reviews,30, 293–331.
Hildebrand M, Staks T and Nieuweboer B, 1990, Pharmacokinetics and pharmacodynamics of Cicaprost in healthy volunteers after oral administration of 5 to 20μG.European Journal of Clinical Pharmacology,39, 149–153.
Honn KV, Cicone B and Skoff A, 1981, Prostacyclin: a potent antimetastatic agent.Science,212, 1270–1272.
Schirner M and Schneider MR, Antimetastatic potential of the stable prostacyclin analogue Cicaprost. In: Vane J and Rubanyi G, eds.Prostacyclin: New Perspectives in Basic Research and Novel Therapeutic Indications, pp. 247–275. Amsterdam: Elsevier, 1992.
Costantini V, Fuschiotti M, Allegrucci G, Agnelli G, Nenci GG and Fioretti MC, 1988, Platelet-tumor cell interaction: effect of prostacyclin and a synthetic analogue on metastasis formation.Cancer Chemotherapy and Pharmacology,22, 287–297.
Sava G, Perissin L, Zorzet S, Piccini P and Giraldi T, 1989, Antimetastatic action of the prostacyclin analogue Iloprost in the mouse.Clinical and Experimental Metastasis,7, 671–678.
Schneider MR, Schillinger E, Schirner M, Skuballa W, Stürzebecher CS and Witt W. Effect of prostacyclin analogues inin vivo tumor models. In: Samuelsson B, Paoletti R and Ramwell RW, eds.Advances in Prostaglandin, Thromboxane, and Leukotriene Research, Vol. 21b, pp. 901–908. New York: Raven Press, 1990.
Schirner M and Schneider MR, 1991, Cicaprost inhibits metastases of animal tumors.Prostaglandins,42, 451–461.
Schirner M and Schneider MR, 1992, The prostacyclin analogue Cicaprost inhibits metastasis of tumors of R3327 MATLu prostate carcinoma and SMT 2A mammary carcinoma.Journal of Cancer Research and Clinical Oncology,118, 497–501.
Neri A, Welch D, Kawaguche T and Nicolson GL, 1982, Development and biologic properties of malignant cell sublines and clones of a spontaneously metastasizing rat mammary carcinoma.Journal of the National Cancer Institute,68, 507–517.
Lichtner RB, Erkell LJ, Schirrmacher V and Nicolson GL, 1989, Effects of RA233 treatment of the adhesive, invasive and metastatic properties of 13762NF rat mammary tumor cells.Clinical and Experimental Metastasis,7, 175–186.
Skuballa W, Schillinger E, Stürzebecher CS and Vorbrüggen H, 1986, Synthesis of a new chemically and metabolically stable prostacyclin analogue.Journal of Medicinal Chemistry,29, 313–315.
Stürzebecher CS, Haberey M, Müller B, Schillinger E, Schröder G, Skuballa W, Stock G, Vorbrüggen H and Witt W, 1986, Pharmacological profile of a novel carbacyclin derivative with metabolic stability and oral activity in the rat.Prostaglandins,31, 95–109.
Levine AS. The biology of human cancer and the development of a rational basis for treatment. In: Kaiser HE, ed.Cancer Growth and Progression, Vol. 1, pp. 1–24. Dortrecht: Kluwer Academic Publisher, 1989.
Zacharski LR. Rationale for anticoagulant treatment of cancer. In: Honn KV and Sloane BF, eds.Haemostatic Mechanisms and Metastasis, pp. 100–120. Boston: Martinus Nijhoff, 1984.
Gasic GJ, 1984, Role of plasma, platelets, and endothelial cells in tumor metastasis.Cancer and Metastasis Reviews,3, 99–116.
Merriman RL, Shakelford KA, Tanzer LR, Campell IB, Bermis KG and Matsumoto K, 1989, Drug treatment for metastasis of the Lewis Lung Carcinoma. Lack of correlation between inhibition of lung metastasis and survival.Cancer Research,49, 4509–4516.
Honn KV, Busse WD and Sloane BF, 1983, Prostacyclin and thromboxane. Implication for their role in tumor cell metastasis.Biochemical Pharmacology,32, 1–11.
Honn KV, 1983, Inhibition of tumor cell metastasis by modulation of the vascular prostacyclin thromboxane A2 system.Clinical and Experimental Metastasis,1, 103–114.
Mahalingam M, Ugen KE, Kao KJ and Klein PA, 1988, Role of platelets in experimental metastasis studies with cloned murine fibrosarcoma cell variants.Cancer Research,48, 1460–1464.
Segaloff E, 1966, Hormones and breast cancer.Recent Progress in Hormone Research,22, 351–379.
Bogden AE. Therapy in experimental breast cancer models. In: McGuire NL, ed.Breast Cancer, Vol. 2, pp. 283–336. New York: Plenum, 1978.
Estrada I and Nicolson GL, 1985, Tumor cell-platelet aggregation does not correlate with metastatic potential of rat 13762NF mammary carcinoma tumor cell clone.International Journal of Cancer,34, 101–105.
Nicolson GL, 1988, Differential organ tissue adhesion, invasion, and growth properties of metastatic rat mammary carcinoma.Breast Cancer Research and Treatment,12, 167–176.
Nicolson GL, Lembo TL and Welch DR, 1988, Growth of the mammary adenocarcinoma cells in semisolid clonogenic medium not correlated with the spontaneous metastatic behavior: Heterogeneity in the metastatic, antigenic, enzymatic, and drug sensitivity properties of cells from different sized colonies.Cancer Research,48, 399–404.
McCulloch P and George WD, 1989, Warfarin inhibits metastasis of MTLn3 rat mammary carcinoma without affecting primary tumor growth.British Journal of Cancer,59, 179–183.
McCulloch P and George WD, 1987, Warfarin inhibition of metastasis: the role of anticoagulation.British Journal of Surgery,74, 879–887.
Lichtner RB, Hutchinson G and Hellmann K, 1985, Antiplatelet pyrimido-pyrimidines and metastasis.Cancer Treatment Reviews,12, 211–234.
Smith WL, 1989, The eicosanoids and their biochemical mechanisms of action.Biochemical Journal,259, 315–324.
Gorman RR, Bunting S and Miller OV, 1977, Modulation of human platelet adenylate cyclase by prostacyclin (PGX).Prostaglandins,13, 377–386.
Müller B, Schmidtke M and Witt W, 1988, Adherence of leukocytes to electrically damaged venulesin vivo.Eicosanoids,1, 13–17.
Honn KV, Grossi IM, Diglio CA and Taylor JD. Role of 12-lipoxygenase metabolites and integrine by glycoprotein receptors in metastasis. In: Etievant C, Cros C and Rustum YM, eds.New Concepts in Cancer, Vol. 3, pp. 42–62. Houndsmills: Macmillan, 1990.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schirner, M., Lichtner, R.B. & Schneider, M.R. The stable prostacyclin analogue Cicaprost inhibits metastasis to lungs and lymph nodes in the 13762NF MTLn3 rat mammary carcinoma. Clin Exp Metast 12, 24–30 (1994). https://doi.org/10.1007/BF01784330
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01784330